17
November
TCM – Brief – Nonrated – On course to fulfill 2022F guidance
In October, TCM posted solid business results with revenue of USD13.5mn (+17% yoy) and NPAT of USD0.8mn (+917% yoy mainly thanks to better cost management and removal of COVID-19 related cost incurred in Oct 2021). Overall, in 10M22, the company achieved USD156.4mn (+25% yoy) in revenue and USD9.8mn in NPAT (+99% yoy), fulfilling 88% and 91% of its 2022F guidance, respectively.